The company’s RAD 101 imaging molecule identified brain tumours in all 12 treatment-naïve patients in a proof-of-concept ...

Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 ...

F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach ...

Radiopharm Theranostic (RADX)s announced the publication of a novel imaging approach demonstrating proof-of-concept for the use of RAD 101 for ...

Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden: Paris, France Wednesday, January 29, 2025, ...

METHODS: One hundred ten patients with gliomas who underwent [18F]FET PET/MR scanning were retrospectively analyzed. The TRFET over MR was identified by the discrepancy-PET that the extent of ...

Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer. PYLCLARI® (INN: Piflufolastat (1 ...

Scientists have developed two new imaging agents that work better than the only currently approved one for detecting tau ...

Life Molecular Imaging (LMI), an international pharmaceutical company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging, announces that the U.S. Food and ...

(Science Signaling) Brain hypometabolism began to evolve during the prodromal stage of dementia with Lewy bodies, with changes on 18F-fluorodeoxyglucose PET paralleling progressive symptoms.